Logo image
Combined Buprenorphine and Clonidine for Short-Term Opiate Detoxification: Patient Perspectives
Journal article   Peer reviewed

Combined Buprenorphine and Clonidine for Short-Term Opiate Detoxification: Patient Perspectives

Mark C. Wallen, William J. Lorman and Joyce L. Gosciniak
Journal of addictive diseases, v 25(1), pp 23-31
15 Mar 2006
PMID: 16597570

Abstract

buprenorphine clonidine Opiate detoxification opiate withdrawal
The approval in 2003 for the use of buprenorphine in opiate addiction treatment has provided physicians with a new pharmacological tool to combat opiate addiction. We surveyed a sample of 100 inpatients who completed short-term opiate detoxification treatment utilizing a combination of buprenorphine and clonidine to assess patient perspectives regarding the usefulness and tolerability of this medication regimen and to compare it to their past opiate detox experiences, if any. Patients identified pain (63%), sleep problems (57%), and anxiety (56%) as the symptoms they perceived to be most helped with buprenorphine. Over 90% of patients with past detoxification treatments rated buprenorphine treatment to be as good as or better than their past treatments. Reports of a euphoric effect were minimal (7%) and no patients reported any generalized worsening of their opiate withdrawal symptoms. We conclude that based upon patient perspectives that combining buprenorphine with clonidine is a useful and well-tolerated medication regimen for the treatment of opiate withdrawal.

Metrics

4 Record Views
9 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Substance Abuse
Logo image